Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Ren, Tianyi; Li, Xiaoyan; Fan, Jian‐Gao

doi:10.3350/cmh.2020.0298

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are some drugs with hypolipidemic effects that can improve the symptoms of NAFLD, they may be accompanied by adverse side effects ( Romero-Gomez et al, 2017 ; Neuschwander-Tetri, 2020 ). Increasing numbers of studies have demonstrated that probiotics can effectively reduce endotoxemia, improve gut barrier function, and may play a certain role in the treatment of NAFLD ( Wang et al, 2020 ; Ferguson and Finck, 2021 ; Luo et al, 2021 ; Ren et al, 2021 ; Huang et al, 2022 ). As the most studied probiotic bacteria, Lactobacillus is an important member of the maintenance of microbial flora in the gut, and some strains have been widely used in the field of food and health and have been developed as probiotics ( Liang et al, 2020 ; Zhang et al, 2020 ; Lee et al, 2021 ; Yu et al, 2021 ; Zhu et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats

Wen

Liu

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Atherosclerosis and non-alcoholic fatty liver disease (NAFLD) have been increasing at an alarming rate worldwide. Many clinical studies have underlined the link between NAFLD and atherosclerosis. Our previous experiments have discovered that Lactobacillus (L.) plantarum ATCC14917 supplementation could decrease the progression of atherosclerotic lesion formation. In this study, we aimed to investigate the role of supplementation of L. plantarum ATCC14917 mitigates liver injury in rats fed with a high-fat diet (HFD, 45% kcal from fat). A total of 32 rats were randomly divided into four groups, including two intervention groups, who fed with HFD and administering either 1 × 107 or 1 × 109 colony forming units (CFU) of L. plantarum ATCC14917, the normal control group, and the HFD control group. The results showed that supplementation with low-dose and high-dose of L. plantarum ATCC14917 for 8 weeks could alleviate the body weight gain (p < 0.05), hepatic steatosis, and serum lipid metabolism (p < 0.05) in HFD-fed rats. Moreover, supplementation of L. plantarum ATCC 14917 decreased total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels (p < 0.05) in serum, and improved HFD-associated inflammation (p < 0.05). Furthermore, cecal contents were analyzed by high-throughput 16S ribosomal RNA sequencing. The results indicated that supplementation of L. plantarum ATCC 14917 could ameliorate HFD-induced gut dysbiosis. In summary, our findings suggest that supplementation of L. plantarum ATCC 14917 could mitigate NAFLD in rats, suggesting it may be considered as a probiotic agent for preventing HFD-induced obesity.

show abstract